Table 1.

Clinical investigation of immunotherapeutic strategies targeting TAMs in MM

Strategy	Agent	Description	Clinical trial ID	Phase	Status
Reducing TAMs	None
Reprogramming TAMs	None
Inhibiting CD47-SIRPα Checkpoint	TTI-621	SIRPα-IgG1 Fc fusion protein	NCT02663518	Phase Ib	Recruiting
	TTI-622	SIRPα-IgG4 Fc fusion protein	NCT03530683	Phase Ia/Ib	Recruiting
	AO-176	Humanized IgG2 anti-CD47 mAb	NCT04445701	Phase I/II	Recruiting
	SRF231	Fully human anti-CD47 mAb	NCT03512340	Phase Ia/Ib	Completed
Overcoming Immunosuppression	BI-505	Fully human anti-ICAM-1 mAb	NCT01025206	Phase I	Completed
	BI-505	Fully human anti-ICAM-1 mAb	NCT02756728	Phase I/II	Terminated
Reversing drug resistance	None

mAb, monoclonal antibody; MM, multiple myeloma; SIRPα, signal regulatory protein α; TAMs, tumor-associated macrophages.